Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

ClinicalTrials.gov ID: NCT07223814

Public ClinicalTrials.gov record NCT07223814. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Bleximenib or Placebo in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for the Treatment of Patients With Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a Double-blind Phase 3 Study

Study identification

NCT ID: NCT07223814
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland; Other
Enrollment: 875 participants

Conditions and interventions

Conditions

Acute Myeloid Leukemia

Interventions

Bleximenib Drug
Cytarabine Drug
Daunorubicin or Idarubicin Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 28, 2026
Primary completion: May 31, 2030
Completion: Nov 30, 2033
Last update posted: Jul 13, 2026

2026 – 2033

United States locations

U.S. sites: 6
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
US-San Francisco CA-UCSF	San Francisco	California	94115	Recruiting
US-Atlanta GA-EMORY	Atlanta	Georgia	30322	Recruiting
US-Kansas City KS-KUMC	Kansas City	Kansas	66103	Recruiting
US-Baltimore MD-UMGCCC	Baltimore	Maryland	21201	Recruiting
US-St Louis MO-WASHU	St Louis	Missouri	63110	Recruiting
US-Cincinnati OH-CINCY	Cincinnati	Ohio	45219	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07223814, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 13, 2026 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07223814 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →